menu search

Open society foundations announce 2023 soros justice fellows

New York, Nov. 03, 2023 (GLOBE NEWSWIRE) — The Open society Foundations is pleased to announce the 20...

November 3, 2023, 8:52 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Travere therapeutics announces late-breaking data from phase 3 studies of sparsentan in igan and fsgs published in the lancet and the nejm respectively and presented at the american society of nephrol

Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney funct...

November 3, 2023, 2:46 pm

Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)

– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development ...

November 3, 2023, 12:30 pm

Could the next black swan event be a cyberthreat?

The rarity, unpredictability, and substantial challenges that Black Swan occurrences offer to financial institutions distinguish them. Black Swan inci...

November 3, 2023, 11:34 am

Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) ann

Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for t...

November 3, 2023, 10:00 am

Poolbeg's lead asset to be in the spotlight at leading medical conference

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said the potential of its lead asset will be discussed at a leading medical conference in December. A poste...

November 3, 2023, 3:32 am

Individual with down syndrome runs first world major at the tcs new york city marathon

New York, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) — Daniel Chaplin, 33, of Homewood, AL will be running in the TCS New York City Marathon for the Nationa...

November 2, 2023, 7:24 pm

In8bio to present new positive data from phase 1 trial of inb-100 at 2023 american society of hematology (ash) annual meeting

New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; up...

November 2, 2023, 1:17 pm

Autolus therapeutics reports third quarter 2023 financial results and business updates

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biolog...

November 2, 2023, 11:11 am

In8bio to present new positive data from phase 1 trial of inb-100 at 2023 american society of hematology (ash) annual meeting

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta ...

November 2, 2023, 9:17 am

Corvus pharmaceuticals to present new interim soquelitinib data from its phase 1/1b t cell lymphoma trial at the 65th american society of hematology (ash) annual meeting & exposition

BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today ...

November 2, 2023, 9:15 am

Vincerx pharma to present three posters at ash 2023 in december

VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favora...

November 2, 2023, 9:10 am

Centessa pharmaceuticals to present additional 52-weeks of continuous treatment data from third year of ongoing phase 2a study of serpinpc for the treatment of hemophilia at american society of hemato

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w...

November 2, 2023, 9:09 am

Centessa pharmaceuticals to present additional 52-weeks of continuous treatment data from third year of ongoing phase 2a study of serpinpc for the treatment of hemophilia at american society of hemato

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w...

November 2, 2023, 9:09 am

Molecular partners to present initial data from ongoing phase 1/2a trial of mp0533 for patients with relapsed/refractory aml and aml/mds at the 65th ash annual meeting and exposition

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (...

November 2, 2023, 2:00 am

Children’s home society of nc celebrates november as national adoption month

Greensboro, NC, Nov. 01, 2023 (GLOBE NEWSWIRE) — During November, Children’s Home society of NC (CH...

November 1, 2023, 2:25 pm

Lirum therapeutics presents positive data on lx-101, a novel clinical-stage targeted therapy, demonstrating potent preclinical activity against pediatric sarcomas

New York, NY, Oct. 31, 2023 (GLOBE NEWSWIRE) — Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focuse...

October 31, 2023, 5:27 pm

Xilio to host virtual investor conference call and webcast on monday, november 6, 2023 to review progress across pipeline, including phase 1/2 clinical data for xtx202, a tumor-activated, engineered,

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and devel...

October 31, 2023, 9:15 am


Search within

Pages Search Results: